China's Pharmaceutical Industry 15th Five-Year Plan, Reported 18 September 2026, Lists Quantum Computing for Drug R&D; the 2021 Plan Did Not
Quentir Medicine Monitor
Evidence-based insights for quantum medicine. Published by Quentir Systems LLC · September 19, 2026.
On 18 September 2026 Chinese business media reported that the Ministry of Industry and Information Technology and nine other central departments had issued a five-year plan for the pharmaceutical industry that lists quantum computing among the technologies the state wants applied to drug research. The predecessor plan of December 2021 listed artificial intelligence, cloud computing and big data for the same job, and the word quantum did not appear in its published text.
The underlying document, which this Monitor knows through the reports of it rather than from the notice itself, is the 15th Five-Year Plan for the pharmaceutical industry, filed as MIIT joint planning document 2026 number 210 and covering 2026 to 2030. In its passage on frontier technologies, as quoted by the business press, it asks industry, universities, research institutes and hospitals to speed up the use of artificial intelligence, quantum computing, supercomputing and computational medicine in drug research and development. The same plan sets a target that Chinese first-in-class drugs make up at least 25 percent of the global total by 2030.
A planning document is a statement of intent, not a result. For a reader who buys for a hospital or runs a pharmaceutical research group in Europe, its value lies in what it tells you about where Chinese public money, procurement and regulatory attention will go for the rest of the decade, and in the gap between the plan's language and the evidence a physicist in Shanghai asked the same industry to produce a week earlier.
What the plan reported on 18 September 2026 contains: ten signatories, eight directions, 25 tasks and the 2030 targets
The ten signatories are the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Natural Resources, the Ministry of Agriculture and Rural Affairs, the Ministry of Commerce, the National Health Commission, the Ministry of Emergency Management, the National Healthcare Security Administration, the National Administration of Traditional Chinese Medicine and the National Medical Products Administration.
The plan was reported on the morning of 18 September by Xinhua, whose wire says the departments issued it "recently" and carries the headline figures; the business press of the same morning gives 18 September as the issue date, and this Monitor has not seen the notice itself. By 2030 the revenue of pharmaceutical manufacturers above the statistical size threshold is to exceed 3.5 trillion yuan, the innovative-drug segment is to grow at least 20 percent a year, at least five Chinese products are to sell more than one billion dollars a year worldwide, at least 200 innovative medical devices are to be approved over the period, fifty companies are to pass 10 billion yuan in annual revenue, and twenty industrial parks are to reach the 100-billion-yuan scale.
An official interpretation republished by China News Service from the MIIT website adds a research-intensity target for listed pharmaceutical companies of at least 10 percent and counts the plan's structure: eight directions and 25 key tasks. The eight directions, in the ministry's own order, are innovation-driven development; resilience and security; digital and intelligent transformation; precision diagnosis and treatment; efficiency improvement; value creation; inclusive health; open and mutually beneficial cooperation.
The passage that concerns this Monitor sits under the heading on laying out frontier technologies and products. As reported by 21st Century Business Herald on the morning of 18 September, it instructs the sector to "accelerate the use of new technologies such as artificial intelligence, quantum computing, supercomputing and computational medicine to empower drug research and development," to explore production models such as beyond-limit manufacturing, space pharmaceuticals and biomanufacturing, to deepen gene editing, precise molecular delivery, cell programming, advanced omics and next-generation brain-computer interfaces, and to break through on organoids and organs-on-chips, universal cell therapy, theranostic radiopharmaceuticals and xenotransplanted organs. In that quoted passage quantum computing appears once, inside a list of four computational tools, with no target, budget line or milestone attached to it; whether the full text attaches one elsewhere is a question this Monitor cannot answer without the notice.
A Sina Finance column posted at 05:32 Beijing time on 20 September, which is the evening of 19 September in Europe and the Americas, whose author had read the full text, reports one more detail that the wire services skipped: the plan's third box, which sorts frontier technologies by stage, places "quantum generative AI drug molecule design" in the basic-research column beside RNA three-dimensional structure prediction and data-storage technology. If that reading is right, the drafters put quantum methods where a research director would put them: before technology transfer and well before industrial maturity. This Monitor has not inspected the full plan text and reports the box placement on the columnist's authority.
Why the 2021 plan chose AI, cloud and big data, and what the shift to quantum computing signals
The comparison with the previous plan is exact because the previous plan is public. The 14th Five-Year Plan for the pharmaceutical industry, MIIT joint planning document 2021 number 217, was issued by nine departments in December 2021 and published on the State Council website on 31 January 2022. Its paragraph on research technology reads, in translation: explore the application of artificial intelligence, cloud computing and big data in research, and raise the efficiency of discovering new targets and new drugs through mining of biological data and simulation. This Monitor extracted the text of the plan's published PDF, linked from that notice page, and searched it: the character pair for quantum does not occur anywhere in the 2021 plan, while artificial intelligence occurs four times. Nearly five years later the same ministry's list reads AI, quantum computing, supercomputing, computational medicine.
Two things changed in between, and neither of them is a validated quantum drug. The first is the national quantum program itself: as this Monitor's defense desk described in August, China is assembling a quantum industry through provincial capital and Party mandate, and a sectoral plan that leaves quantum computing unmentioned would now be out of step with the central line. The second is the maturing of the computational-chemistry use case in the published literature, which the Medicine desk has followed paper by paper: emulated variational calculations on small molecules, docking problems compressed onto a handful of qubits, and peptide-folding runs on trapped-ion hardware. Those results are real and small. The plan's single sentence does not distinguish between them and the marketing language that circulates around them.
Quantum pillar: computing. Technology readiness: not applicable. The document is a state planning instrument for 2026 to 2030 that names quantum computing as a research tool to be applied; it reports no device, no algorithm and no clinical or preclinical result of its own, so there is no rung on the readiness ladder to assign.
Why Lu Chaoyang's Bund Summit warning about "quantum new drugs" now sits beside a state plan
A week before the plan appeared, the physicist Lu Chaoyang of the University of Science and Technology of China told the 2026 Bund Summit in Shanghai that some Chinese companies were selling "quantum new drugs" as packaged products while leading research groups still offered prize money for a practical quantum algorithm. This Monitor covered that remark on 13 September and noted the question a Xinmin Evening News commentator asked in reply: why the correction had to come from a scientist, and why no regulator had said what a company may call quantum.
None of the published reports of the new plan mention an answer to that question. The plan is co-signed by the National Medical Products Administration, the regulator for drug approval and labeling in China, and no report of the document describes a definition of what a company may call quantum. What it does contain is a legitimizing sentence: a company that wants to raise money on a quantum drug-discovery story can now cite a ten-ministry planning document that instructs the sector to accelerate exactly that. On the Hong Kong exchange on the morning of 18 September, Gelonghui reported through Sina Finance that XtalPi Holdings (2228.HK) rose more than 12 percent intraday to 7.755 Hong Kong dollars on the plan's release and a Stanford collaboration, and the same market note described the company's "quantum physics plus AI plus automated robotics" drug-discovery platform as the benchmark of the research paradigm the policy supports. Two distinctions matter here. "Quantum physics" in that platform description refers to quantum-mechanical calculation on classical computers, and the wording establishes neither the use of quantum-computing hardware nor any quantum computational advantage. And the plan endorses a direction of research; it certifies no company, no platform and no molecule.
What a European pharmaceutical R&D head or hospital buyer can use from a Chinese planning document
Three uses are practical. First, procurement direction. The eight directions and the 2030 targets tell a supplier of computational-chemistry software, quantum-cloud access or high-performance computing where Chinese demand will be pushed by the state through 2030, and, if the column's reading of the basic-research box is right, that supplier would expect grant-funded academic and hospital consortia rather than production pipelines as the first customers, in line with the plan's call for joint work among companies, universities, research institutes and medical institutions.
Second, a calibrated reading of Chinese company claims. When a Chinese firm's prospectus or press release describes its quantum drug-discovery platform as aligned with national policy, policy alignment alone does not establish whether the platform uses quantum hardware or demonstrates quantum advantage, because the policy sentence sets no threshold. The evidence questions do not change: which molecule, which calculation, which classical baseline, which wet-lab confirmation, and which of those results has appeared in a peer-reviewed venue. If the column's reading is right, the plan's own drafters filed the quantum item under basic research, which says the same thing.
Third, a benchmark for planning elsewhere. The Chinese document shows what it looks like when a government writes a frontier computational method into a sectoral industrial plan before the method has produced a drug. The plan's 2030 targets, 25 percent of the world's first-in-class drugs, five products above one billion dollars in annual sales and 200 approved innovative devices, measure the industry as a whole and can be met with no quantum computer involved. Whether the quantum sentence proves foresight or hype can only be judged on quantum-specific results with a classical comparison: a molecule, a calculation, a strong classical method on the same problem, and a wet-lab confirmation, published where others can check them.
How Quentir Reads It
The significant fact in the 18 September plan is the change of list between two documents from the same ministry, nearly five years apart: artificial intelligence, cloud computing and big data in December 2021; artificial intelligence, quantum computing, supercomputing and computational medicine in September 2026. That change measures the rise of quantum computing in Chinese industrial policy, and nothing else. It carries no evidence about what quantum hardware can do for a molecule today, and the reported placement of quantum generative design in the basic-research box suggests the drafters would agree.
For the Evidence Register this Monitor maintains, the document is filed as a policy instrument with no readiness rung, a useful anchor for reading the flood of Chinese company statements that will cite it. The next checkable event is the first provincial implementation plan or ministry call for projects that attaches money to the quantum sentence. Funding alone earns no readiness level; a level can be assigned only when a funded project publishes a result that can be placed on the ladder.
Sources
Primary source: the Ministry of Industry and Information Technology of the People's Republic of China and nine other departments, "Pharmaceutical Industry Development 15th Five-Year Plan," MIIT joint planning document 2026 number 210, reported on 18 September 2026 by Xinhua and 21st Century Business Herald and interpreted on the MIIT website as republished by China News Service; the notice itself was not inspected. Also drawn on: the 14th Five-Year Plan for the pharmaceutical industry, MIIT joint planning document 2021 number 217, as published on gov.cn on 31 January 2022; a Sina Finance column of 20 September 2026 on the plan's technology boxes; the PANews English summary of 18 September 2026; and earlier Quentir coverage. The comparison between the two plans and the readiness placement are this Monitor's own.